Know ME/CFS.

What it is

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME/CFS) is a serious, complex, multi-system neurological disease. The defining feature is not fatigue, it is post-exertional malaise: a delayed, disproportionate worsening of every symptom after the smallest exertion. Patients pay back days or weeks in bed for things healthy people do without noticing.

In 2015 the U.S. Institute of Medicine (now the National Academy of Medicine) reviewed the evidence and formally classified ME/CFS as a serious, biological disease, not a psychiatric or behavioural one. The 2021 NICE guideline in the UK reached the same conclusion and formally repudiated graded exercise therapy.

ME/CFS is not deconditioning. It is not depression. It is not laziness. Multiple studies have found that ME/CFS patients rate their quality of life lower than patients with multiple sclerosis, congestive heart failure, late-stage cancer, or stroke. The severe end of the disease is among the worst chronic illness any clinician will see, and the patients are usually invisible because they cannot leave bed.

Disease overview

Estimates run from 0.4% to over 1% of the population, with sharp post-2020 increases driven by Long COVID. Roughly 75% of patients are women, with onset peaks in adolescence and the mid-thirties. The majority of cases follow an identifiable trigger: a viral infection (Epstein-Barr, influenza, enteroviruses, SARS-CoV-2), a surgery, severe trauma or stress, or pregnancy. Some begin gradually with no clear inciting event.

The course varies. Some patients improve substantially, especially in the first two years and especially in adolescents. Most stabilise at a reduced baseline and improve in fits and starts with careful pacing and comorbidity treatment. A meaningful minority decline to the severe or very-severe end, sometimes triggered by a single push-through episode or an aggressive exercise programme.

Core symptoms

Severity, and what it actually means

The Bateman Horne Center scale, widely used in patient communities and increasingly by clinicians, distinguishes four levels:

• Mild. Roughly 50% of previous function. Can usually maintain part-time work or studies with careful pacing. Most weeks contain a partial crash. Outsiders often cannot see the illness.
• Moderate. Roughly 25 to 50% of previous function. Cannot sustain full-time work. Most days dominated by symptom management; ordinary errands cost a recovery day. Mobility aids start to make sense.
• Severe. Mostly housebound. Significant assistance needed for daily activities. Showering and feeding oneself are often the most ambitious activity of the day. Most clinicians never see these patients in person.
• Very-severe. Bedbound, often unable to tolerate light, sound, moving images, music, speech, or touch. Communication may be via pen and paper. Some patients are tube-fed. Capacity exists for almost nothing.

Causes and biological mechanisms

The mechanism is not fully understood. The strongest contributing pictures, each supported by published research, include:

• Post-viral immune activation. Most ME/CFS cases begin after a viral infection. Persistent immune activation, reactivated herpesviruses (EBV, HHV-6), and an enduring inflammatory state have all been documented.
• Autonomic and cerebral blood flow dysfunction. Most patients meet POTS criteria, and transcranial Doppler studies show large drops in cerebral blood flow on standing even when heart rate and blood pressure look near-normal.
• Mitochondrial impairment. Reduced ATP production, abnormal oxidative metabolism, and impaired aerobic recovery (the post-exertional crash that defines PEM) have been measured repeatedly.
• Endothelial dysfunction and microclots. Recent work (2024 to 2026) frames ME/CFS and Long COVID as endothelial diseases: damage to the lining of blood vessels causing tissue hypoperfusion, with circulating microclots blocking small vessels.
• Autoantibodies. Antibodies against adrenergic and muscarinic receptors are found at elevated rates. The BC007 trial (which neutralises some of these antibodies) is one of the most-watched drug candidates in the field.
• Genetic predisposition. A 2025 study identified specific risk loci; hEDS, familial dysautonomia, and ME/CFS show heritable clustering.
• Triggers. Infection (EBV, influenza, COVID-19, enteroviruses), surgery, trauma, severe stress, pregnancy, mould exposure, and concussion are all documented precipitants.

Related conditions and overlaps

ME/CFS rarely travels alone. Most patients also meet criteria for POTS. The trifecta of POTS, hypermobile EDS, and MCAS is heavily over-represented. Fibromyalgia, gastroparesis, endometriosis, small fibre neuropathy, sleep apnea, iron deficiency, and migraine are routinely under-treated comorbidities that can move severity levels when addressed. Chapter six covers each in depth.

Support for family and loved ones

The hardest thing for the people around a ME/CFS patient to understand is the delay. The patient looks fine at 2pm and is non-functional by Wednesday. That is not erratic behaviour. It is the disease's central mechanism. Believing the patient about the delayed cost of activity is the single most useful thing a loved one can do.

What helps: taking the cancellations, doing the cognitive labour (medications, appointments, paperwork), running interference with the people who suggest exercise, being the calm voice that says no when the patient is being asked to push. What hurts: implying they would feel better if they tried harder, reading a good week as recovery, and any version of 'I read about a person who cured themselves with [protocol].'

Living with an invisible illness

ME/CFS is invisible to everyone except the patient. The disability is in the delay: the cost of today's activity arrives in two days. To everyone else, a person at lunch on Sunday looks like someone who is fine on Sunday. The wreckage on Tuesday happens in private, behind closed doors, after the cancellation.

Patients learn early that the world judges by what it can see. Showing up to a wedding for an hour means the people who care about you assume the illness must be mild. The recovery that follows, often a week in bed, is invisible. The judgement is what becomes visible. Over time, many patients stop trying to explain.

The PACE / GET legacy

The single largest event in ME/CFS clinical history is the PACE trial: a UK-based study published in 2011 that promoted graded exercise therapy (GET) and CBT as primary treatments for ME/CFS. The trial was run primarily by psychologists, used outcome thresholds that classified some patients as 'recovered' while they were still severely disabled, and shaped clinical guidance globally for more than a decade.

Patients reported harm. Surveys consistently found that more than half of patients undergoing graded exercise programmes got worse, with a meaningful minority becoming severely or permanently more disabled. The trial's data were eventually obtained under freedom-of-information laws, re-analysed independently, and the headline 'recovery' findings did not hold up.

In 2021, NICE (the UK clinical guidance body) updated its ME/CFS guideline and explicitly removed GET as a recommended treatment, citing patient harm. The U.S. CDC quietly removed similar guidance years earlier. Many clinicians, particularly older ones, still recommend GET. Patients should expect this and be ready to decline, in writing if necessary.

Medical gaslighting

The PACE legacy left a generation of clinicians believing ME/CFS is a psychological condition that responds to behaviour change. Many ME/CFS patients have been told the illness is depression, deconditioning, somatisation, or 'just stress.' They have been refused workups, refused referrals, and pushed into exercise programmes that made them worse.

The fix is largely clinician-by-clinician. Patients who find one ME/CFS-literate clinician (often through Bateman Horne Center, the Open Medicine Foundation registries, or local patient communities) describe the experience as transformative, not because the medicine is suddenly different, but because they are believed and not asked to make themselves worse to prove they are sick.

Severe and very-severe ME/CFS

The severe end of the spectrum is a hidden population. These patients cannot leave their homes. The very-severe cannot leave their beds, often cannot tolerate light, sound, or human voice, and may communicate only by writing or by holding up cards. Some patients have stopped speaking with family members for years not from anger but because the sound of their voice triggers a crash.

Clinicians almost never see these patients, because the patients cannot travel to clinics. Research almost never includes them, because they cannot fill out questionnaires or sit through tests. The medical literature systematically underestimates the upper limit of how bad this disease can get. The community that does see them, families, MEAction's #MillionsMissing campaign, dedicated severe-ME advocates, has been the primary source of the picture.

If you or someone you love is at the severe end: minimal-stimulation environments, eye masks and ear protection, fed-and-cleared liquid diets when chewing is too much, communication via cards, and an advocate who will speak for the patient at appointments matter more than any single medication. The Bateman Horne severe-ME care guidelines are the best public-facing clinical resource.

Impact on identity

ME/CFS frequently strikes high-functioning people in their prime. Doctors, engineers, athletes, parents of small children. The identity loss is sharp, and the bargaining stage is long. Patients describe trying every protocol, every supplement, every retraining programme, looking for the version of themselves they used to be. Most eventually find a different stability: a smaller life lived with intention, defined around energy rather than ambition.

This is not surrender. It is the work of integrating an illness rather than fighting it. The patients who do best at this almost universally describe the same arc: fighting hard for years, hitting a wall, accepting the disease as a constraint to design around, then finding meaning inside the constraint.

Social isolation

Most social life requires energy ME/CFS patients do not have. Dinners, parties, in-person meetings, even long phone calls cost real recovery time. Patients withdraw not from preference but from arithmetic. Many find their most sustaining community online, where text-based, asynchronous interaction fits within the envelope. The r/cfs subreddit and severe-ME-specific spaces are some of the most generous, well-moderated patient communities anywhere.

Mental health

Depression and anxiety are common in ME/CFS, and the relationship is widely misunderstood by clinicians. Living with a serious, dismissed, energy-limiting illness produces depression and anxiety as natural consequences. Treating the depression rarely resolves the ME/CFS, and antidepressants chosen for energetic patients (SSRIs) often hit ME/CFS patients badly. SNRIs, low-dose tricyclics, and low-dose abilify are often better-tolerated where pharmacological help is wanted.

ME/CFS reaches every body system because the disease lives at the intersection of immune, autonomic, neurological, and energy-production failure. The pattern below is comprehensive, not a checklist. No patient has every symptom, but most have something from each cluster.

Post-exertional malaise (PEM)

PEM is the defining feature of ME/CFS and the single thing that distinguishes it from chronic fatigue, deconditioning, depression-related tiredness, and most other fatigue-dominant illnesses. Without PEM, the diagnosis is not ME/CFS.

What PEM is. A delayed, disproportionate worsening of all symptoms after exertion that a healthy person would barely notice. Typically appears 12 to 72 hours after the trigger, though some patients crash within minutes or several days later. Can last hours, days, weeks, or in severe cases permanently lower the patient's baseline.

What can trigger PEM. Physical activity, cognitive activity (a long conversation, sustained reading, a stressful email), emotional intensity (joyful or distressing), sensory load (a noisy restaurant, bright lights), heat, alcohol, an infection. Patients learn that "exertion" includes any sustained engagement with the world, not just movement.

What PEM feels like. Patients describe it as flu-like (aches, sore throat, swollen glands), with severe brain fog, profound fatigue, increased sensory sensitivity, sleep disturbance, and often a sense of having been poisoned.

Neurological and cognitive

Brain fog

Slowed thinking, word-finding loss, short-term memory disruption, difficulty following conversation. In moderate ME/CFS, patients describe reading a paragraph and being unable to recall it ten seconds later. In severe ME/CFS, patients lose the ability to read, to recognise familiar faces, or to find their own name when asked. The term 'brain fog' minimises what can functionally resemble temporary aphasia or dementia. Neuropsychological testing in moderate ME/CFS routinely shows processing-speed decrements equivalent to being 20-30 years older.

Sensory sensitivity

Light, sound, smell, touch, and temperature can feel overwhelming. Severe patients may need blackout curtains, eye masks, ear protection, and minimal-stimulation environments. Even ambient indoor light or a partner's voice can trigger PEM in very-severe patients.

Headaches and orthostatic head pressure

Tension headaches, migraine, and the 'coat-hanger' neck and shoulder pain associated with cerebral hypoperfusion on standing are common.

Tinnitus and dizziness

Frequent, often worse during PEM. Mild balance issues and visual snow (a persistent screen-static effect across the visual field) are reported by a meaningful subset.

Air hunger and breathlessness

A sense of not getting enough air despite normal oxygen levels. Often misread as anxiety. Severe dysautonomia can produce sensations of being electrocuted or convulsions when nerves "feel on fire," and these episodes can themselves trigger PEM.

Sleep

Unrefreshing sleep

The cardinal sleep feature. Patients fall asleep but wake feeling unrested, often more tired than when they went to bed. Sleep architecture studies show reduced slow-wave (deep, restorative) sleep and frequent micro-arousals.

Reversed circadian rhythm

A surprisingly common pattern in ME/CFS, MCAS, and Long COVID: foggy and exhausted on waking, slowly clearer through the day, clearest around 7pm, then second wind running into late-night insomnia. The mechanism is not fully understood; possibly related to cortisol curve disruption.

Severe insomnia

Some patients, particularly post-COVID, develop intractable insomnia: unable to sleep for days even on prescription sleep medication. This is medical emergency territory; aggressive treatment is warranted.

Autonomic and cardiovascular

Orthostatic intolerance

The majority of ME/CFS patients meet POTS criteria or have measurable cerebral hypoperfusion on standing. Heart rate, blood pressure, and cerebral blood flow can each be deranged. Specialised tilt-table tests adding transcranial Doppler and end-tidal CO2 capnography can reveal cerebral hypoperfusion even when heart rate and blood pressure look near-normal.

Temperature dysregulation

Heat intolerance, abnormal sweating, cold extremities. Heat exposure (hot showers, summer, fevers) is a common PEM trigger. Cold can be paradoxically painful, "the chill goes straight to the bones."

Resting tachycardia and HR instability

Many patients have an elevated resting heart rate and large day-to-day variability in heart rate variability (HRV) that tracks symptom severity. Wearable HRV data is increasingly used both for diagnosis support and for daily pacing decisions.

Immune and systemic

Recurrent sore throat and swollen glands

Often dismissed by patients who have learned to ignore them. Consciously checking against the diagnostic criteria often reveals that frequent mild sore throats and tender lymph nodes have been a chronic feature.

Flu-like malaise

A baseline sense of being mildly unwell, especially during PEM. Many patients describe it as 'always slightly fluey.'

Mast cell activation

MCAS can develop in long-standing ME/CFS with no prior allergy history. Sometimes triggered by supplements (B3 flush, zinc, certain B-vitamin protocols). Symptoms include flushing, hives, food reactions, GI symptoms, and unexplained reactions to medications.

Reactivated herpesviruses

EBV, HHV-6, and other latent viruses are often reactivated. Antiviral trials in this subset are ongoing but unproven.

Pain

Muscle and joint pain

Diffuse, often migratory. Many ME/CFS patients also meet criteria for fibromyalgia. Chronic pain is real, under-acknowledged, and often dismissed in favour of focusing on fatigue. Max-dose paracetamol/Tylenol may only blunt rather than relieve it; some patients need prescription pain medication.

Nerve pain

Burning, electric, and stabbing pain consistent with small fibre neuropathy is found in a significant subset. Skin biopsy can confirm.

Abdominal pain

Common, often related to gastroparesis (delayed stomach emptying), IBS, or dysautonomia-related gut dysmotility.

Diagnostic criteria

ME/CFS is diagnosed clinically. There is no single confirmatory blood test. Three sets of criteria are widely used:

• IOM 2015 (NAM). The most accessible. Requires substantial reduction in pre-illness activity for at least six months, post-exertional malaise, unrefreshing sleep, AND either cognitive impairment or orthostatic intolerance.
• Canadian Consensus Criteria (CCC, 2003). Stricter. Requires PEM plus pain plus neurocognitive plus autonomic/neuroendocrine/immune symptoms. Used in much of the research literature.
• International Consensus Criteria (ICC, 2011). Strictest. Requires PENE (post-exertional neuroimmune exhaustion) plus features across multiple body systems. Best matched to the severe end of the spectrum.

For most patients, an IOM 2015 diagnosis is enough to access care and disability paperwork. The stricter criteria matter mostly for research participation and for distinguishing ME/CFS from chronic fatigue conditions without PEM.

Tests and workup

The purpose of testing is not to confirm ME/CFS but to rule out the major mimics and identify treatable comorbidities. Reasonable initial workup:

• Full blood count, ESR, CRP. Anaemia, infection, gross inflammation.
• TSH, free T4, morning cortisol. Thyroid and adrenal insufficiency.
• Ferritin, B12, folate, vitamin D, magnesium. Deficiencies that mimic or worsen ME/CFS. Note: 'low-normal' ferritin (under 75) is functionally deficient for many patients.
• HbA1c, comprehensive metabolic panel. Diabetes, electrolyte and renal issues.
• ANA, RF, anti-CCP. Lupus, rheumatoid arthritis, other autoimmune.
• EBV, CMV, HHV-6 serology. Reactivated herpesvirus pattern.
• Active stand test or tilt-table test. Most ME/CFS patients meet POTS criteria; treating it changes outcomes.
• Sleep study. Sleep apnea is the most-missed treatable mimic; if there is any chance, ask.
• Skin biopsy for small fibre neuropathy. When neuropathic pain is prominent.
• Gastric emptying study. When GI symptoms are prominent.

Differential diagnosis

Conditions that can look like ME/CFS or coexist with it:

• Sleep apnea (the single most-missed treatable mimic)
• Hypothyroidism / Hashimoto's
• Iron deficiency (ferritin under 75 is functionally deficient)
• Vitamin B12 / D / folate deficiency
• Adrenal insufficiency
• Lyme disease and tick-borne co-infections (region-dependent)
• Chronic infections (EBV, HHV-6, HIV, hepatitis)
• Autoimmune disease (lupus, MS, Sjögren's)
• Major depression
• Long COVID (overlap rather than differential, but worth naming)
• Fibromyalgia (overlapping, not exclusive)
• POTS, hEDS, MCAS (often comorbid)

Finding your energy envelope

The energy envelope is the daily activity ceiling below which a patient does not trigger PEM. It is highly individual, varies day to day, and shrinks during flares. The work of pacing is finding the envelope and staying inside it.

• Track activity vs. PEM. For two to four weeks, log activity in 30-minute blocks (light, moderate, heavy) alongside symptom severity. Patterns become visible: 'I crash 36 hours after sustained reading,' 'I crash same-day after standing more than 15 minutes.'
• Use heart rate as a proxy. Many patients identify an anaerobic threshold (typically 60 to 80% of (220 minus age)) above which exertion triggers PEM. Staying below this with a chest strap or wrist-based monitor is the most common quantitative pacing method.
• Include cognitive and emotional load. Reading a long article, a difficult conversation, a stressful work meeting all count. Many patients overestimate physical limits and underestimate cognitive ones.
• Bank rest, plan crashes. Some events are worth a crash. Bank extra rest before, plan recovery days after, accept that the cost will come. This is a deliberate pacing decision, not failure.

Pacing protocols

Several structured pacing approaches are used, each with different tradeoffs:

• Heart-rate ceiling pacing. Stay below your anaerobic threshold (often the calculated value or, more precisely, the value from CPET testing if available). Use a fitness watch with alarms. Conservative, evidence-aligned, and widely recommended.
• Time-budget blocks. Divide the day into 30-minute or 1-hour blocks; assign activity levels (rest, light, moderate) based on baseline; reserve recovery blocks proactively.
• Energy envelope (Jason). Build a personalised baseline; stay at or below it; expand only after months of stability. Slower than feels comfortable, often the right answer.
• Micro-exercise. For some moderate patients, very short bursts of resistance work (30 seconds every 30 minutes) can build capacity without triggering PEM, but only with careful PEM monitoring and only after baseline stability.

Medications

No medication is approved specifically for ME/CFS itself. Patients use off-label medications to manage core symptoms (sleep, pain, autonomic) and to treat comorbidities. Most-tried in the community:

• Low-dose naltrexone (LDN, 1.5–4.5 mg). The single most-discussed off-label ME/CFS medication. Modulates microglial inflammation. Multiple patients report meaningful function gains; well-tolerated; cheap. Worth a trial.
• Mestinon (pyridostigmine). Improves nerve signalling to blood vessels. Helps the POTS picture in many ME/CFS patients; some report near-immediate strength gains.
• Low-dose abilify (LDA, 0.25–2 mg). A growing off-label option, especially for cognitive symptoms and reversed circadian rhythm. The Stanford ME/CFS clinic has published case series.
• Low-dose amitriptyline or nortriptyline. Sleep and pain. Often tolerated at very low doses (5–10 mg) when full doses are not.
• POTS medications. Beta blockers, ivabradine, midodrine, fludrocortisone, all useful where POTS is comorbid (most patients).
• Sleep medications. Trazodone, melatonin, mirtazapine; for severe insomnia, prescription options when over-the-counter fails.
• Antivirals. Valacyclovir, valganciclovir for patients with active EBV/HHV-6 reactivation; the evidence base is limited but real for a subset.
• Pain medication. Tramadol, low-dose opioids in carefully selected patients. SNRIs (duloxetine) where pain and depression overlap.

Most ME/CFS patients are exquisitely sensitive to medication, often needing one-quarter to one-half of standard adult doses. Start low, titrate slowly, expect setbacks. Allow 6 to 8 weeks per medication trial.

Non-drug approaches

• Aggressive rest at illness onset. The strongest predictor of better long-term outcomes in post-viral cases is heavy rest in the first weeks; this is opposite to standard 'push back into activity' advice. If you are early, rest is treatment.
• Sleep hygiene tailored to ME/CFS. Standard sleep advice (cap at 7-8 hours, no naps) is calibrated for healthy people; many ME/CFS patients function best with 10-11 hours and a nap. Listen to your own pattern.
• Cooling, heat avoidance, sensory minimisation. Same lifestyle work as POTS for the autonomic side.
• Salt and fluid loading. For the POTS-overlap subset, 2 to 3 L water and 8 to 10 g sodium daily can help significantly.
• Diet experimentation. Low-histamine, gluten-free, and anti-inflammatory diets help some patients, particularly those with MCAS overlap. Treat individually; no universally recommended ME/CFS diet exists.
• Stress reduction (genuinely, not 'fix your thoughts'). Meditation, gentle breath work, mindfulness can help with the autonomic load. Different category entirely from brain-retraining cure programmes; covered separately under Experimental.

The GET / push-through warning, in detail

Graded exercise therapy, brain-retraining programmes promising cure, and any structured 'push through the symptoms' approach has caused documented permanent harm in ME/CFS patients. The pattern repeats across decades of patient surveys:

• Patient starts the programme at moderate severity.
• Initial weeks feel manageable; the prescriber takes this as proof of progress.
• Cumulative PEM builds. Patient deteriorates over weeks or months.
• By the time the prescriber notices, the patient is at a permanently lower baseline.
• Withdrawal from the programme stabilises the patient but rarely restores the lost ground.

If you have been prescribed GET, a brain-retraining programme, or any push-through approach, you are within your rights to decline. NICE removed GET from its ME/CFS guideline in 2021 explicitly citing patient harm.

What helps versus what harms

Experimental and emerging

This section honestly maps the experimental landscape. Inclusion is not endorsement; community caveats are explicit.

• BC007. A drug that neutralises autoantibodies against adrenergic and muscarinic receptors. Phase 2 trials are running for Long COVID and (in parallel) ME/CFS. Among the most-watched candidates in the field.
• CAR-T cell therapy. One case-report of remission in autoimmune disease has fuelled hope that immune 'reset' approaches could work for autoimmune-driven ME/CFS. Years away from being widely available.
• Microclot dissolution (triple anticoagulation). Heparin/clopidogrel/apixaban regimens explored for the endothelial-dysfunction subset. Real research interest; serious bleeding risk; not for self-treatment.
• IVIG and plasmapheresis. For patients with strong evidence of an autoimmune mechanism. Expensive, with risks, reserved for severe refractory cases.
• Low-dose tirzepatide and other GLP-1s. Anecdotal reports of large functional gains in some patients. Mechanism unclear, possibly anti-inflammatory.
• Brain retraining (DNRS, Gupta, Pain Free You, Born Free Protocol). Heavily contested. Some patients report benefit, plausibly via stress reduction. Community consistently flags the harm pattern: framing the disease as a learned nervous-system pattern can shade into 'staying sick is your fault,' and patients who abandon pacing to try a cure programme can crash hard. The Born Free Protocol in particular is a non-peer-reviewed self-published programme requiring 50+ supplements daily, with no medical-trained author. Approach with eyes open, never as a substitute for foundational care.
• Faecal microbiota transplantation, methylene blue, cellular medicine, etc. All discussed in patient communities, none with peer-reviewed evidence for ME/CFS efficacy at present.

Tools, apps, and the kit patients actually use

The ME/CFS toolkit is largely about pacing accurately, tracking patterns clinicians will accept, and engineering an environment that does not constantly trigger PEM.

Pacing and wearables

• Rox. The companion app this reference is built alongside. Connects your wearable to your symptom log, PEM events, and patterns. Built-in pacing layer: heart-rate ceiling, energy-envelope tracking, and an interpretation layer that turns months of data into something a clinician can act on. App Store.
• Heart-rate ceiling pacing on any wearable (Apple Watch, Garmin, Fitbit, Polar, Whoop, Oura). Set an alarm at your anaerobic threshold; chest straps are more accurate than wrist-based for sustained low intensity.
• Visible (armband + app). Continuous HRV-based exertion tracking with "pace points" per task. Designed for the ME/CFS / Long COVID / POTS cluster. Heavily discussed in r/cfs; community is genuinely split on whether the subscription cost is justified given the depth of insight.
• Polar chest strap (H10). The community's reference standard for accurate HR at low intensities where wrist-based watches drift.

Sensory and environmental kit

• Eye mask (Manta or similar) and blackout curtains. Daily essentials in severe ME/CFS.
• Loop or noise-cancelling earplugs. Reduce ambient sensory load.
• Bedside table with everything within reach. Water bottle, electrolytes, medications, snacks, phone charger. Standing to retrieve things you forgot is the most-paid-for unnecessary exertion.
• Shower stool (IKEA BÄSINGEN is the community favourite). Showering is one of the most expensive activities in ME/CFS.
• Mobility aids for high-cost days. A rollator with a seat, a wheelchair for travel and crowds, a fold-out cane-seat. Using them does not accelerate the illness; it makes a wider life possible.
• Letter board, communication cards, or pen and paper for severe-end patients when speech is too costly.

Diet and supplement basics

• Electrolytes (LMNT, SaltStick, SODII, NUUN, or home ORS) for the POTS-overlap subset. Start with the sodium math.
• Iron, B12, vitamin D, magnesium if labs support, with attention to "low-normal" ferritin under 75.
• Single supplement at a time. ME/CFS sensitivity to interventions is high; changing one variable per 4-8 weeks is the way to know what is doing what.

Finding the right clinician

• Bateman Horne Center physician resources and clinical practice guidelines.
• Open Medicine Foundation for research links and clinical centres.
• MEAction patient-advocacy hub and local action chapters.
• Patient-curated "Clinicians Who Care" lists by region.

Prognosis

Honest prognosis for ME/CFS is harder to give than for most chronic illness. Most studies are small, biased toward people well enough to participate, and pre-date the post-2020 Long COVID expansion of the patient population.

What is reasonably established:

• Spontaneous full recovery is uncommon, possibly 5-15% of cases, most often in adolescents and within the first two years.
• Most patients stabilise at a reduced baseline and improve in fits and starts over years, particularly with careful pacing and comorbidity treatment.
• A meaningful minority decline, often after a single push-through episode or an aggressive exercise prescription, and may not recover the lost ground.
• Severe and very-severe patients can and do improve, sometimes dramatically. A patient who spent four years bedbound in a dark room walking outside and working part-time again is rare but not unheard-of.

The pattern most patients should expect to plan for: not a return to who you were, but a workable life inside the constraint, with intermittent good periods and rare strong periods, sustained by pacing and the right comorbid treatments.

Recovery stories, with caveats

The online ME/CFS recovery-story ecosystem is large and heavily contested. A few things worth knowing before reading them:

• Many 'recovery' stories come from patients who were mild to begin with, optimised wellness aggressively, regained roughly 20% of function, and redefined that as recovery. That is real and valuable, and also not the same as moving from severe to mild.
• Many recovery stories come from people who never had PEM and never met ME/CFS criteria. Generic chronic fatigue has a different prognosis.
• The recovery-story creator ecosystem (YouTube, podcasts) selects for the recovered. Patients who tried the same protocol and got worse rarely make videos. Survivorship bias is the entire genre.
• Brain-retraining and 'cure protocol' content frequently implies that staying sick is the patient's fault. This is harmful framing; the community flags it repeatedly.

That said: substantial improvement is possible, and the patients who improve almost universally describe the same arc: aggressive rest at onset, strict pacing, treating comorbidities, finding one good clinician, and accepting the disease as a long arc rather than a problem to solve in six months. Be skeptical of cure narratives; be open to the patient stories of slow, hard-won improvement.

Self-directed care

Because ME/CFS spans neurology, cardiology, immunology, sleep medicine, and rheumatology, patients usually become their own care coordinators. The skills that matter:

• Pacing accurately, with quantitative tools (HR ceiling, time blocks, envelope tracking).
• Knowing your comorbidities and pushing for each to be treated.
• Tracking medication trials carefully so you know what is doing what.
• Maintaining a flare plan you can hand to a partner or caregiver.
• Educating one clinician at a time, with documentation.

This is genuine cognitive work, and pacing it inside the energy envelope matters. Rox is built to take this load off your plate where possible: tracking, pattern-finding, and turning months of wearable data into the patterns a clinician will actually act on.

Daily functioning

• Mornings are often the worst window. Reversed circadian rhythm is common; many patients function best in the late afternoon and early evening.
• Standing tasks are deceptively expensive. Cooking, showering, queueing each cost recovery hours. A stool in the kitchen, shower stool, and bedside-everything help significantly.
• Cognitive tasks count. Email, difficult conversations, anything requiring sustained attention all draw on the same energy budget as physical activity.
• Heat is a major variable. Hot showers, summer, fevers can turn a manageable week into a difficult one.
• Travel costs disproportionately. A round-trip to a clinic appointment can cost the rest of the day; cross-time-zone travel can cost weeks.

Relationships

ME/CFS is hard on relationships. The partner of an ME/CFS patient often becomes a part-time caregiver. Friends fade because the patient cannot keep up the cadence of social contact. Family can be the worst, sometimes refusing to believe the illness is real after years.

Patient-community-tested advice:

• Be honest about the illness early, in writing where possible. Vague descriptions ('I get tired easily') invite vague expectations.
• Educate one person who will be your advocate, especially for medical appointments. The cognitive load of advocacy alone is too high during flares.
• Dating with ME/CFS is possible. Many patients in the community recommend declaring the illness in dating profiles; it reduces anxiety and filters for people who can show up. Pacing plus medication has been part of multiple successful long-term relationships.
• Children: deeply individual. Some patients have parented through ME/CFS with substantial caregiver help and a smaller life designed around it; others would not do it again. Be honest with yourself about energy and support.

Work and disability

Working with ME/CFS depends heavily on severity, the flexibility of the role, and how aggressively the patient paces. The honest summary:

• Mild ME/CFS: often compatible with part-time or remote, accommodated work. Pacing remains essential.
• Moderate ME/CFS: full-time work is usually unsustainable; many patients reduce hours, move to remote, or transition to disability over months.
• Severe and very-severe ME/CFS: work is not possible. Disability paperwork becomes the primary structural task.

Start the disability paperwork early. ME/CFS disability claims are routinely denied initially; it often takes a year and an appeal. Document everything: PEM episodes, activity vs. crash patterns, ME/CFS-literate clinical letters, comorbidity diagnoses (POTS, MCAS, hEDS, sleep apnea each strengthen the claim). The Bateman Horne Center has clinician-facing letter templates that can be shared with your doctor.

Severe-end caregiving

Caregiving for severe or very-severe ME/CFS is one of the hardest tasks in chronic illness, partly because clinicians rarely visit and partly because the patient often cannot tolerate the very stimuli (light, sound, conversation) that ordinary care involves.

What helps:

• Minimal-stimulation environment: blackout curtains, white noise or silence, even light fixtures dimmed.
• Pen-and-paper or letter-board communication; respect that speech itself is exertion.
• Liquid or pre-prepared meals when chewing is too much.
• Personal-care assistance with absolutely minimal conversation.
• Advocacy at appointments; the patient cannot speak for themselves.
• The Bateman Horne severe-ME care guideline as a reference for clinicians who have never seen the severe end.

Caregivers should build their own support network. Caregiver burnout in severe ME/CFS is real and serious; ME-specific caregiver communities (often via MEAction local chapters and Facebook severe-ME caregiver groups) exist and are valuable.

Adapting life around the illness

The patients who do best, sustainably, all describe the same arc: a year or two of fighting hard for the old self, hitting a wall, accepting the disease as a constraint, then designing a meaningful life inside the constraint. This is not surrender, it is the integration work that makes the long arc possible.

Practical engineering that helps:

• Build the environment around the illness: bedside-everything, shower stool, mobility aids by default, cooling vest in summer.
• Choose accessible activities: reading, audiobooks, short asynchronous social contact, low-stakes creative work.
• Lower the metabolic cost of basic care: pre-cooked meals, paid help where possible, the unsentimental decisions about laundry and cleaning.
• Build slack into every plan; expect the cost two days later.
• Find one or two people who will keep believing the illness even on good days.

ME/CFS rarely travels alone. Most patients meet criteria for multiple overlapping conditions, and treating each one separately can move a whole severity level even when the ME/CFS itself doesn't change. Recognising the overlaps is one of the most useful things a patient can do.

POTS (Postural Orthostatic Tachycardia Syndrome)

Most ME/CFS patients meet POTS criteria on a properly-done active stand test. The two diseases share autonomic dysfunction, post-viral triggers, and a substantial portion of patient population. Treating the POTS part (beta blockers / ivabradine, fluids and sodium, compression, midodrine, fludrocortisone) often delivers the biggest functional improvement in ME/CFS. The POTS reference on this site goes deeper.

The trifecta: hEDS, MCAS, and POTS

Hypermobile Ehlers-Danlos Syndrome (hEDS), Mast Cell Activation Syndrome (MCAS), and POTS co-occur so often that clinicians now treat them as one triad. ME/CFS patients are heavily over-represented in this triad. Patient surveys suggest that ADHD and autism are also over-represented (sometimes called AuDHD; informal estimates run as high as 50%), possibly via shared connective-tissue, autonomic, and immune mechanisms.

• hEDS. Joint hypermobility, frequent sprains, dislocations and ligament tears, easy bruising, family history of "double-jointed" or scoliosis. Screen with the Beighton score; refer to genetics if positive.
• MCAS. Flushing, hives, food and drug reactions, GI symptoms, unexplained reactions, dermatographism (skin that develops welts when scratched). Treatment is H1/H2 antihistamines, mast-cell stabilisers (ketotifen, cromolyn), low-histamine diet.
• POTS. See above. Stand test is the cheap diagnostic.

Long COVID

Long COVID has become the most common known new trigger for ME/CFS. A substantial portion of people with persistent post-COVID symptoms (estimates range from a third to over half in some cohorts) meet IOM 2015 ME/CFS criteria. The wave of new patients has, paradoxically, driven the largest burst of ME/CFS research funding in decades. Many of the most-watched experimental treatments (BC007, triple anticoagulation, GLP-1s) are being explored in Long COVID and ME/CFS in parallel.

Fibromyalgia

Significant overlap (estimates of 30 to 70% of ME/CFS patients also meet fibro criteria), but they are distinct diseases. ME/CFS's defining feature is PEM. Fibromyalgia's defining feature is widespread nociplastic pain. A fibro patient with significant PEM should be evaluated for comorbid ME/CFS, because the presence of PEM changes exercise advice entirely. The fibromyalgia reference covers the central-sensitisation side of the picture in depth.

Small fibre neuropathy (SFN)

Reduced small nerve fibre density on skin biopsy is found in a meaningful subset of ME/CFS patients, particularly those with neuropathic pain or autonomic neuropathic features. The same small nerves that sense pain also control sweating and blood-vessel constriction, linking SFN to the POTS picture. Where neuropathic pain is prominent, a skin biopsy is worth requesting.

GI disorders and gastroparesis

Gastroparesis (delayed stomach emptying), IBS, and other motility disorders are over-represented. The autonomic nervous system runs the gut, so dysautonomia produces GI dysfunction in many ME/CFS patients. Smaller, more frequent meals; separating fluids from food; gastric emptying study where symptoms warrant. Prokinetic medication (low-dose erythromycin, prucalopride) can help.

Endometriosis and hormones

Endometriosis is heavily over-represented in ME/CFS patients. The shared pattern: chronic systemic inflammation, dysmenorrhoea-driven PEM triggers, and routinely-delayed gynaecological diagnosis. Women who menstruate often notice their ME/CFS shifts across the cycle, often worsening premenstrually. Pregnancy outcomes are under-studied; postpartum worsening is common.

Other overlaps worth screening for

• Sleep apnea. The single most-missed treatable mimic. CPAP can substantially improve fatigue in a subset of ME/CFS patients. A sleep study is worth requesting even when you do not think you have apnea.
• Iron deficiency (functional). Ferritin under 75 ng/mL is functionally deficient for many ME/CFS patients even though it is within the lab "normal" range. Repletion can meaningfully reduce fatigue.
• Hashimoto's and other thyroid disease. TSH, free T4, anti-TPO at minimum.
• Reactivated EBV, HHV-6, CMV. Antiviral trials are experimental but real for a subset.
• Adrenal insufficiency. Morning cortisol; very rarely missed, but worth checking.
• Lyme disease and tick-borne co-infections. Region-dependent; chronic Lyme is contested but acute Lyme is genuinely missed.
• Migraine. Over-represented; treatable; can drive significant PEM.
• Vitamin B12, D, magnesium deficiency. All over-represented; cheap to test.
• Chiari malformation and craniocervical instability (particularly in hEDS patients). Suspect when there are neurological features that don't fit the rest of the picture.
• Anxiety and depression. Largely consequences of the illness and its dismissal, but treatment is worthwhile where present; choose medications carefully (SNRIs and low-dose abilify often better-tolerated than SSRIs in ME/CFS).

The current scientific picture

ME/CFS is best understood today as a multi-system disease at the intersection of immune, autonomic, neurological, and energy-production failure. The mechanism is not one thing; it is several reinforcing things:

• Post-viral immune activation. Most cases follow an infection. Persistent immune signatures (cytokine patterns, T-cell exhaustion, glial activation) are documented.
• Endothelial dysfunction. Recent work frames ME/CFS and Long COVID as vascular diseases: damage to blood-vessel lining causes tissue hypoperfusion. A 2026 Cell Death and Disease paper proposes virus-induced endothelial senescence as a driver.
• Microclots. Persistent fibrinoloid microclots blocking small vessels have been identified in subsets of Long COVID and ME/CFS patients.
• Autoantibodies. Antibodies against adrenergic and muscarinic receptors are elevated. The BC007 trial neutralises these antibodies; results awaited.
• Mitochondrial impairment. Reduced ATP production, abnormal aerobic recovery; the Workwell Foundation's 2-day CPET protocol documents impaired post-exertional recovery objectively.
• Cerebral hypoperfusion. On-standing drops in cerebral blood flow are large and reproducible, even when heart rate and blood pressure look near-normal.
• Neuroinflammation. Iwasaki and colleagues have shown immune-mediated CNS inflammation patterns in Long COVID consistent with ME/CFS overlap.

Historical timeline

Active research directions

• BC007. Phase 2 trials for ME/CFS / Long COVID, neutralising autoantibodies against adrenergic and muscarinic receptors.
• CAR-T autoimmune reset. Early case reports suggest immune-cell engineering could put autoimmune-driven dysautonomia and ME/CFS into remission. Years away from broad availability.
• Triple anticoagulation. Heparin / clopidogrel / apixaban regimens for the microclot subset. Research interest is real, bleeding risk is real, no self-treatment.
• Workwell Foundation 2-day CPET. Objective documentation of post-exertional metabolic failure. Useful for disability claims and research stratification.
• NIH RECOVER and Open Medicine Foundation programmes. The biggest research engines currently working on ME/CFS-relevant mechanisms.
• Pacing biomarker research. Wearable HR, HRV, and continuous activity data is being explored as both a diagnostic tool and a real-time pacing aid.
• Microbiome and metabolomics. Distinct gut-microbiome signatures and altered metabolomic patterns in ME/CFS are being characterised.
• Iwasaki preprints on Long COVID neuroimmune mechanisms. Reduced regulatory T cells, pro-inflammatory microglia, persistent NF-kB activation. Highly relevant for ME/CFS-Long COVID overlap.

Key sources worth knowing

• Bateman Horne Center. The single most-cited clinical and educational hub. Clinical practice guidelines, Stanford Symposium recordings, comorbidity write-ups (Dr. Brayden Yellman's 2025 underappreciated-comorbidities talk is heavily referenced in r/cfs).
• Open Medicine Foundation. Patient-organised research funding; runs the You + ME Registry that has powered much of the recent science.
• MEAction. Patient advocacy hub; #MillionsMissing campaign; severe-ME care resources.
• World ME Alliance. International coordination; concise multi-language fact sheets patients use to explain ME/CFS to family and clinicians.
• Health Rising (Cort Johnson). Independent journalism / research-news blog. The community's translator-in-chief for ME/CFS and Long COVID research.
• Workwell Foundation. 2-day CPET research; clinician resources; the strongest objective documentation pathway for severe pacing impairment.
• knowmecfs.org. A patient-built free resource specifically to help partners and loved ones understand the diagnosis.

Content creators worth following

These are the names that come up again and again in r/cfs, r/covidlonghaulers, and the wider ME/CFS community, sorted by what the community actually shares. The Reddit citation under each card is the thread the recommendation traces back to, so you can see why they're trusted (or contested), not just that they are.

Clinical and research centres

Journalism and translation

Documentary, advocacy, and patient voice

Pacing and tracking tools

The contested zone, brain-retraining and recovery-story creators

A large industry markets brain-retraining and "you can cure yourself" programmes for ME/CFS, Long COVID, and the broader cluster. The community is heavily split. Some patients credit them with real improvement; others have been actively harmed by stopping pacing to try a cure. Here are the most-shared, with the controversy made explicit so you can decide.

Resources and community

• r/cfs and r/covidlonghaulers on Reddit. Some of the best-moderated chronic-illness patient communities anywhere. Pacing-aware, severe-ME-aware, brain-retraining-skeptical.
• MEAction local chapters. Country and state-level patient advocacy and support.
• Severe-ME caregiver groups. Often on Facebook; the most practical knowledge for the severe end of the spectrum.
• You + ME Registry (Open Medicine Foundation). Patient-contributed data registry; participating both helps research and connects you to study opportunities.

Where to start if you've just been diagnosed

1. Pace. Aggressive rest if you are within the first year of post-viral onset.
2. Identify and treat comorbidities (POTS, MCAS, hEDS, sleep apnea, iron deficiency, gastroparesis).
3. Refuse GET and any push-through programme. Document your refusal in writing if needed.
4. Get the disability paperwork started early.
5. Find one ME/CFS-literate clinician (Bateman Horne, OMF, MEAction can help).
6. Educate one person who will be your advocate when you can't speak for yourself.
7. Try one off-label medication at a time, starting with LDN. Allow 6-8 weeks per trial.
8. Be skeptical of cure narratives.

About this reference

This is a living document. It will be updated as new research emerges and as patients tell us what is missing. The medical claims here are drawn from the sources listed above (Bateman Horne Center, Open Medicine Foundation, MEAction, World ME Alliance, Workwell Foundation, Health Rising, knowmecfs.org) and the published ME/CFS and Long COVID literature. None of this is personal medical advice. For your situation specifically, talk with a clinician familiar with ME/CFS, preferably one who has read the post-2021 guidance.